Tom McCracken, JD — EVP, General Counsel
Mr. McCracken has over 20 years of experience providing legal guidance and advice to the pharmaceutical and biopharmaceutical industry where he has specialized in shepherding novel therapeutics from conception through development and into commercialization. His experience includes all aspects of intellectual property (IP) legal services, including patent procurement and enforcement and IP transactional matters such as in- and out-licensing, acquisition, divestment and strategic partnerships, as well as providing general legal and corporate matters. Most recently, Mr. McCracken served as General Counsel, Secretary and Compliance Officer for XenoPort, Inc. (acquired by Arbor Pharmaceuticals). Prior to that, he served as Vice President, Intellectual Property for MAP Pharmaceuticals, Inc. (acquired by Allergan), Durect Corporation, and PowderJect Pharmaceuticals plc (acquired by Chiron Vaccines, now Novartis). In addition to his corporate experience, Mr. McCracken served in private patent practice, advising clients in the areas of gene therapy, immunization and vaccines, medical and analytical devices and monoclonal antibody products. He earned his B.A. in Microbiology from the University of California, San Diego, and his J.D. from Santa Clara University.